Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v4-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2019-08-13 | 2019-08-13 |
Drug Identification Number | 02243333 | 02243333 |
Brand name | FERRLECIT | FERRLECIT |
Common or Proper name | Ferrlecit | Ferrlecit |
Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
Ingredients | IRON | IRON |
Strength(s) | 12.5MG | 12.5MG |
Dosage form(s) | LIQUID | LIQUID |
Route of administration | INTRAVENOUS | INTRAVENOUS |
Packaging size | 10 | 10 |
ATC code | B03AC | B03AC |
ATC description | IRON PREPARATIONS | IRON PREPARATIONS |
Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated start date | 2019-09-30 | 2019-09-30 |
Actual start date | ||
Estimated end date | 2019-11-30 | 2019-11-30 |
Actual end date | ||
Shortage status | Anticipated shortage | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | Delay in testing - Sanofi-aventis Canada Inc. would like to inform health care providers of an anticipated potential shortage for FERRLECIT, which may be caused by a delay in standard testing. It is possible that the situation is resolved by the beginning of September, in which case stock availability would not be affected. However due to the importance of this medication, we are communicating this situation as early as possible. The anticipated resolution date provided for this potential shortage is our best conservative estimate at this time. Allocation of current stock is in place to ensure availability of the product for as many patients as possible. Allocation is given based on historical purchase figures. | Delay in testing |
Health Canada comments |